State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff

Size: px
Start display at page:

Download "State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff"

Transcription

1 State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff Funding Source: Grant No Robert Wood Johnson Foundation Substance Abuse Policy Research Program Contact info: Lori J. Ducharme, Ph.D., Project Director Institute for Behavioral Research 118 Barrow Hall University of Georgia Athens, GA Web: November

2 Project overview: Buprenorphine (Subutex and Suboxone ) received FDA approval for use in the treatment of opioid dependence on October 8, The drug has been widely regarded as heralding a new era in opioid dependence treatment, owing to the unique circumstances in which it is approved for use. For most of the last 40 years, methadone was the only pharmacotherapy for patients dependent on heroin and other opiates. However, daily dosing, highly restrictive treatment settings, and stigma associated with methadone clinics and the drug s diversion potential limits the number of patients who can receive this treatment. Naltrexone, approved for use in the mid- 1990s, is available in a wider variety of settings, and has little to no abuse potential. However, patient compliance is a persistent issue among physicians prescribing naltrexone, and it still has not been widely adopted by either community treatment programs (Roman & Johnson, 2002) or primary care physicians (Mark et al., 2003; Thomas et al., 2003). In a sense, buprenorphine combines the more appealing characteristics of methadone and naltrexone: it has demonstrated a high degree of clinical effectiveness, its Suboxone formulation has a reduced abuse potential and diversion threat, it can be prescribed for less-than-daily dosing, and it is available in settings other than OTPs. Patients may receive buprenorphine for opioid dependence in one of three treatment settings: opioid treatment programs; community treatment programs (non-methadone) having a DATA-waived physician on staff or contract; or from a DATA-waived primary care physician in an office-based practice. ( DATA-waived physicians are those who qualify for a waiver, as specified under the Drug Abuse Treatment Act of 2000, allowing them to prescribe approved Schedule III and IV narcotics for the treatment of opiate addiction.) Community treatment programs may also provide required counseling and other appropriate ancillary services for patients receiving buprenorphine in an office-based practice, without themselves dispensing buprenorphine on-site. Clinical practice guidelines for the use of buprenorphine in the treatment of opioid dependence were published in mid-2004 (CSAT 2004). As Ling and Smith (2002) are careful to note, buprenorphine is not simply a new medication, but a treatment strategy that exists within a complex social and political context. It is unclear whether or how state and federal policies provide incentives for the adoption of buprenorphine by physicians and addiction treatment providers. In ongoing research at the University of Georgia, we have been tracking the adoption and implementation of a number of pharmacotherapies (including buprenorphine) for the treatment of substance abuse. As we continue to monitor adoption at the treatment provider level, it becomes clear that the state regulatory and funding environment plays an important role in the adoption process, and warrants investigation in and of itself. In our surveys, program directors frequently cite structural barriers to the adoption of buprenorphine, including state policies prohibiting them to prescribe medications; restrictions on insurance reimbursement for the drug; expense relative to methadone; and inconsistent or wholly absent state regulations or guidance on training, credentialing, and approval processed needed to incorporate 2

3 buprenorphine into everyday clinical practice. Thus, it is important to better understand state policy issues and their influence on program-level adoption decisions. The proposed project included multiple phases. The first phase gathered information on the current regulatory and funding (Medicaid) policies in each of the 50 states and the District of Columbia as they pertain to the two established opiate addiction treatment medications (naltrexone and methadone) as well as buprenorphine. These data were gathered from reviews of secondary sources, as well as from brief interviews with key informants within each Single State Agency (SSA) or State Methadone Authority (SMA) office this varied depending on which office within the state assumed regulatory oversight for matters involving opiate addiction treatment. This report summarizes highlights of the SSA/SMA interviews, which occurred in mid These data were then merged with program-level data from SAMHSA s National Survey of Substance Abuse Treatment Services (NSSATS), which provides broad coverage of the United States. More than 11,000 treatment programs were included in the public use datafile for the 2005 NSSATS. Data on state-level policies were included as predictors in multivariate models of buprenorphine adoption. Those findings are summarized on the project s website (www.uga.edu/ntcs/bup_policy.htm). Links to published reports of the study s findings will be made available on that website as they are released. CSAT (2004) Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (TIP 40). Rockville, MD: Center for Substance Abuse Treatment, SAMHSA. Ling W & D Smith (2002) Buprenorphine: Blending clinical practice and research. Journal of Substance Abuse Treatment, 23: Mark T, HR Kranzler & X Song (2003) Understanding US addiction physicians low rate of naltrexone prescription. Drug & Alcohol Dependence, 71: Roman PM & JA Johnson (2002) Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment, 22,

4 Thomas CP, SS Wallack, S Lee, D McCarty & R Swift (2003) Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24:

5 Summary of Survey Responses The following data were obtained from interviews conducted in 2006 with SSA representatives in 49 states (1 refusal). Note: For the purpose of this study, buprenorphine is used generally to refer to either Subutex or Suboxone. OTP = opioid treatment program. Q1. Are there any regulations or policies in [state] beyond regulations at the Federal level that specifically dictate conditions for methadone programs to use buprenorphine? Only 2 states identified any specific conditions for the use of buprenorphine in OTPs. Q2. Does the state provide any incentives to encourage methadone programs to begin offering buprenorphine? If so, what are they? Only 1 state identified any specific incentives to implement buprenorphine in OTPs, and this was limited to a grant earmarked for the training of clinicians in a high risk area of the state. Q3. Are methadone programs required or encouraged to advise patients of the availability of buprenorphine? - 7 states required OTPs to advise patients about buprenorphine s availability - 14 states encouraged OTPs to advise patients about buprenorphine s availability - 28 states had no such policy Q4. What about non-methadone programs that treat substance abuse clients are there any regulations or policies in [state] beyond regulations at the Federal level that specifically define conditions for these programs to use buprenorphine? [This question does not apply to officebased physicians.] Only 1 state identified any policies beyond existing regulations; this state had developed provisions for treatment providers to operate as modified narcotic treatment programs. Q5. Does the state provide any incentives for non-methadone programs to include buprenorphine among their treatment options? 5

6 2 states indicated that such incentives were provided. However, it was unclear whether these incentives (e.g., increased reimbursement rates) were designated specifically for buprenorphine, or to encourage the use of any approved addiction pharmacotherapy. Q6. Has the state funded any clinician training events on buprenorphine? (This may include physician certification classes for DATA waivers, or counselor training or information sessions.) - 26 states (53%) had offered clinician trainings on buprenorphine - 23 states (47%) had not offered trainings Among states that had offered trainings: Most had offered trainings in coordination with the FDA approval of buprenorphine. Most of these states also offered ongoing trainings usually in collaboration with SAMHSA for physicians related to DATA waivers. Far less often did states offer trainings aimed at counselors, treatment program administrators, or other line staff. Q7. Does the state require treatment programs to utilize evidence based practices? - 19 states indicated that treatment programs were required to use EBPs - 28 states cited no such requirements - 2 states did not know; 2 states did not respond Among states that require the use of EBPs, there was no consistent approach to predefining treatment practices considered evidence-based that is to say, only 10 of the 19 states indicated that they had compiled a list of approved practices. Among those, only 3 included buprenorphine on the state s EBP list. Q8. Has the state agency formally issued any guidance to treatment providers about clinical practice for using buprenorphine? - 10 states (20%) indicated that they had issued guidance to treatment providers on using buprenorphine; - 39 states (80%) had not issued any such guidance Q9. The Substance Abuse and Mental Health Services Administration (SAMHSA) recently released two treatment improvement protocols or TIPs providing guidance for the use of buprenorphine by physicians and in methadone treatment settings. Has your office distributed those TIPs to treatment providers in your state, or encouraged providers to review them? 6

7 [Note: this question refers to TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, and TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Both are available from SAMHSA s information clearinghouse at states had not distributed either TIP or were unfamiliar with them - 15 states had encouraged programs to obtain and utilize the TIPs - 23 states had distributed the TIPs (hard copy or electronic copy) 7

8 Q10. Other than through Medicaid, have state funds been used to subsidize the availability of buprenorphine for publicly-funded treatment clients? How? 9 states indicated some limited subsidies for the use of buprenorphine. In each case, these were grants or other limited use of discretionary funds for pilot tests of buprenorphine in a specific clinic or set of clinics. Q11. Other than through Medicaid, have state funds been used to subsidize the availability of counseling and other wraparound services for patients receiving buprenorphine in office-based settings? How? 11 states indicated that such subsidies were available, generally under limited grants for pilot or demonstration projects in a defined number of clinics. Q12. Generally speaking, would you say that the state substance abuse agency - 24 (49%) actively encourage programs to consider using buprenorphine - 24 (49%) have taken no real position on buprenorphine either way - None (0%) actively discourage programs from using buprenorphine Q13. Under federal requirements, physicians need to be certified under the Drug Addiction Treatment Act of 2000 to prescribe buprenorphine. States can impose additional requirements on physicians before they are permitted to prescribe. Does [state] have any special requirements for DATA-waived physicians wishing to prescribe buprenorphine? Only 3 states indicated specific additional requirements for physicians; in each case, physicians were required to register with the state. Q14. Aside from what we ve talked about, is there any pending legislation that would affect treatment programs use of buprenorphine, or do you expect any changes to be made to current policies in the near term? 9 states indicated that there was legislation pending or anticipated. For the most part, these pending actions were related to reimbursement (e.g., Medicaid formularies) or procedural matters (e.g., state pharmacy board procedures). 2 states indicated that they were reconsidering the content of their current OTP regulations. 8

9 Q15. Is methadone maintenance treatment included as a covered benefit in the state s Medicaid plan? (i.e., does Medicaid cover the methadone itself?) - 28 states said that methadone was a covered Medicaid benefit - 17 states said it was not - 4 states did not answer (could not contact knowledgeable respondent) Q16. Is the use of buprenorphine for opioid dependence treatment a covered benefit in the state s Medicaid plan? (Note: it may be listed as Subutex or Suboxone ) 26 states indicated that buprenorphine for substance abuse treatment was a covered benefit Q17. Is buprenorphine (Subutex and/or Suboxone ) currently included in the state s Medicaid formulary or drug list? 28 states indicated that buprenorphine was on the state s Medicaid formulary. The difference between this and the preceding question is that buprenorphine is not exclusively used for addiction treatment, and thus may be on the formulary for other intended uses. Q18. If not included on formulary, are there plans to include it in the near-term? - 5 states indicated that there were plans to include buprenorphine on the formulary; - 5 states indicated that there were no plans to do so; - the remaining states were unsure of plans regarding buprenorphine and Medicaid Q19. Thinking about office-based physicians [doctors in practice outside of addiction treatment programs], do the Medicaid benefits cover physician and medication costs for patients receiving buprenorphine in physician s office settings? - 19 states indicated yes - 19 states indicated no - 11 states did not respond (could not contact knowledgeable respondent) Q20. Does Medicaid cover the costs of counseling and other wraparound services for clients receiving buprenorphine from office-based physicians? 9

10 - 17 states indicated yes - 21 indicated no - 11 states did not respond (could not contact knowledgeable respondent) 10

The Determinations Report: A Report On the Physician Waiver Program Established by the. Drug Addiction Treatment Act of 2000 ( DATA )

The Determinations Report: A Report On the Physician Waiver Program Established by the. Drug Addiction Treatment Act of 2000 ( DATA ) The Determinations Report: A Report On the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 ( DATA ) Submitted by the Center for Substance Abuse Treatment, Substance Abuse

More information

MEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER

MEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER MEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER TWO PRIMARY ACCESS POINTS Pharmacy Benefit Dispensed by a Pharmacy Billed via the PBM Process (NCPCP) Oversight by Drug

More information

Various therapies are used in the

Various therapies are used in the National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Overview of Opioid Treatment Programs within the United States: 2008 In Brief In 2008, a total of 1,132 (8 of all

More information

Use of Pharmacotherapies by Substance Abuse Treatment Facilities

Use of Pharmacotherapies by Substance Abuse Treatment Facilities Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1

More information

Ohio Legislative Service Commission

Ohio Legislative Service Commission Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing

More information

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently

More information

MEDICATION ASSISTED TREATMENT (MAT)

MEDICATION ASSISTED TREATMENT (MAT) MEDICATION ASSISTED TREATMENT (MAT) STATISTICS: ALCOHOL AND OPIOID USE Last year 33 Iowans died from opioid overdose deaths; an additional 19 individuals died of a heroin overdose. The number of drug overdose

More information

Web-Based Resources. Locating Treatment

Web-Based Resources. Locating Treatment Web-Based Resources Locating Treatment http://dpt2.samhsa.gov/treatment/ -- This is the Substance Abuse and Mental Health Services Administration s (SAMHSA) page for locating both public and private opiate

More information

Information for Pharmacists

Information for Pharmacists Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl

More information

Increasing Access to Opioid Addiction Treatment

Increasing Access to Opioid Addiction Treatment Report to The Vermont Legislature Increasing Access to Opioid Addiction Treatment In Accordance with Act 75, 2013, Section 14b An Act Relating to Strengthening Vermont s Response to Opioid Addiction and

More information

Methadone. Buprenorphine 10/9/2015

Methadone. Buprenorphine 10/9/2015 Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious

More information

National Alliance of Methadone Advocates

National Alliance of Methadone Advocates National Alliance of Methadone Advocates 435 Second Avenue New York, NY 10010 Voice/Message/Fax Education Series Number 10 (212) 595-NAMA June 2003 The New Federal Regulations What Do They Mean for Patients?

More information

American Society of Addiction Medicine

American Society of Addiction Medicine American Society of Addiction Medicine Public Policy Statement on Office-based Opioid Agonist Treatment (OBOT) BACKGROUND Methadone maintenance treatment of opioid addiction was developed in 1965 and implemented

More information

Counselor Attitudes Toward Pharmacotherapies for Alcohol Dependence

Counselor Attitudes Toward Pharmacotherapies for Alcohol Dependence Counselor Attitudes Toward Pharmacotherapies for Alcohol Dependence Lori J. Ducharme, Ph.D. Hannah K. Knudsen, Ph.D. Paul M. Roman, Ph.D. University of Georgia 1 Counselors, Pharmacotherapies, and Alcohol

More information

Behavioral Health Barometer

Behavioral Health Barometer Behavioral Health Barometer EXECUTIVE SUMMARY Region IV, 2014 Atlanta Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International

More information

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment: Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society

More information

SUBOXONE /VIVITROL WEBINAR. Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12

SUBOXONE /VIVITROL WEBINAR. Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12 SUBOXONE /VIVITROL WEBINAR Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12 WEBINAR INTRODUCTIONS Cynthia Parsons- Program Manager

More information

State Perspectives on Buprenorphine and Office-Based Treatment

State Perspectives on Buprenorphine and Office-Based Treatment State Perspectives on Buprenorphine and Office-Based Treatment The National Association of State Alcohol and Drug Abuse Directors (NASADAD) For the Center for Substance Abuse Treatment (CSAT) With support

More information

ARCHIVED BULLETIN. Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E

ARCHIVED BULLETIN. Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E BULLETIN INTELLIGENCE Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III drug has been made available for use

More information

Using Buprenorphine in an Opioid Treatment Program

Using Buprenorphine in an Opioid Treatment Program Using Buprenorphine in an Opioid Treatment Program Thomas E. Freese, PhD Director of Training, UCLA Integrated Substance Abuse Programs Director, Pacific Southwest Addiction Technology Transfer Center

More information

This module will assist participants to:

This module will assist participants to: BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module V: Coordinated Care Effective Coordination of Care Effective coordination combines the strengths of various systems

More information

Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis

Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,

More information

Revenue Streams Associated with the Implementation of Medication-Assisted Treatment for Opioid Dependence

Revenue Streams Associated with the Implementation of Medication-Assisted Treatment for Opioid Dependence Revenue Streams Associated with the Implementation of Medication-Assisted Treatment for Opioid Dependence Hannah K. Knudsen, Ph.D. Amanda J. Abraham, Ph.D. Lauren O Brien Paul M. Roman Acknowledgements

More information

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This

More information

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics

More information

BUPRENORPHINE TREATMENT

BUPRENORPHINE TREATMENT BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West

More information

MEDICAL POLICY Treatment of Opioid Dependence

MEDICAL POLICY Treatment of Opioid Dependence POLICY........ PG-0313 EFFECTIVE......11/11/14 LAST REVIEW... 07/14/15 MEDICAL POLICY Treatment of Opioid Dependence GUIDELINES This policy does not certify benefits or authorization of benefits, which

More information

Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course

Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,

More information

An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009

An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009 An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009 Background Defining the problem: Opiates pain relievers (OxyContin,

More information

H.R Children's Health Act of As cleared by the Congress on September 27, 2000, and signed by the President on October 17, 2000

H.R Children's Health Act of As cleared by the Congress on September 27, 2000, and signed by the President on October 17, 2000 CONGRESSIONAL BUDGET OFFICE PAY-AS-YOU-GO ESTIMATE October 31, 2000 H.R. 4365 Children's Health Act of 2000 As cleared by the Congress on September 27, 2000, and signed by the President on October 17,

More information

Expanding the Use of. Creating Change on the Ground: Opportunities and Lessons Learned from the Field

Expanding the Use of. Creating Change on the Ground: Opportunities and Lessons Learned from the Field Expanding the Use of Medications to Treat Individuals with Substance Use Disorders in Safety-Net Settings Creating Change on the Ground: Opportunities and Lessons Learned from the Field September 2014

More information

RE: Medication Assisted Treatment for Opioid Use Disorders RIN 0930-AA22

RE: Medication Assisted Treatment for Opioid Use Disorders RIN 0930-AA22 May 31, 2016 Substance Abuse and Mental Health Services Administration Department of Health and Human Services ATTN: Jinhee Lee, SAMHSA 5600 Fishers Lane Room 13E21C Rockville, MD 20857 RE: Medication

More information

U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health

U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health TESTIMONY of the American Medical Association before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Re: Examining Legislative Proposals to Combat our Nation's

More information

FISCAL IMPACT STATEMENT. LS 7351 NOTE PREPARED: Feb 6, 2015 BILL NUMBER: SB 464 BILL AMENDED: Feb 5, 2015

FISCAL IMPACT STATEMENT. LS 7351 NOTE PREPARED: Feb 6, 2015 BILL NUMBER: SB 464 BILL AMENDED: Feb 5, 2015 LEGISLATIVE SERVICES AGENCY OFFICE OF FISCAL AND MANAGEMENT ANALYSIS 200 W. Washington, Suite 301 Indianapolis, IN 46204 (317) 233-0696 http://www.in.gov/legislative FISCAL IMPACT STATEMENT LS 7351 NOTE

More information

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,

More information

Appendices to Interim Report on the Baltimore Buprenorphine Initiative. Managed Care Organization Information Pages

Appendices to Interim Report on the Baltimore Buprenorphine Initiative. Managed Care Organization Information Pages Appendices to Interim Report on the Baltimore Buprenorphine Initiative Appendix A Managed Care Organization Information Pages Appendix B Buprenorphine Online Physician Training Information Packet Appendix

More information

Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services

Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services Maryland Integrative Learning Community Lynn H Albizo, Director of Public Affairs Maryland Addictions Directors

More information

Evidence-Based Treatment for Opiate-Dependent Clients: Availability, Variation, and Organizational Correlates

Evidence-Based Treatment for Opiate-Dependent Clients: Availability, Variation, and Organizational Correlates The American Journal of Drug and Alcohol Abuse, 32: 569 576, 2006 Copyright Q Informa Healthcare ISSN: 0095-2990 print/1097-9891 online DOI: 10.1080/00952990600920417 Evidence-Based Treatment for Opiate-Dependent

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

Office-based Treatment of Opioid Dependence with Buprenorphine

Office-based Treatment of Opioid Dependence with Buprenorphine Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures

More information

Medication Assisted Treatment

Medication Assisted Treatment Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice

More information

Federal Regulations For Prescribing Scheduled Controlled Substances

Federal Regulations For Prescribing Scheduled Controlled Substances Federal Regulations For Prescribing Scheduled Controlled Substances HEIT TEMPLATE.PPT 1 Central Principle of Balance With the Use of Controlled Substances Dual imperative of government Establish a system

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy

More information

Practice Protocol. Buprenorphine Guidance Protocol

Practice Protocol. Buprenorphine Guidance Protocol Practice Protocol Buprenorphine Guidance Protocol Developed by the Arizona Department of Health Services Division of Behavioral Health Services Effective Date: 02/23/11 Title Buprenorphine Guidance Protocol

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call

More information

Physician Information. Answers to Frequently Asked Questions

Physician Information. Answers to Frequently Asked Questions Page 31 Physician Information Answers to Frequently Asked Questions Who is qualified to prescribe SUBOXONE or SUBUTEX? Physicians who: Meet one or more of the following training requirements Hold a subspecialty

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

SAMHSA Initiatives to Educate Prescribers and Consumers and Treatment Resources

SAMHSA Initiatives to Educate Prescribers and Consumers and Treatment Resources SAMHSA Initiatives to Educate Prescribers and Consumers and Treatment Resources Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services Administration 1 Overview National

More information

Summary: There are four major initiatives underway that address integration of substance abuse care with physical and mental health.

Summary: There are four major initiatives underway that address integration of substance abuse care with physical and mental health. Summary: Section E.306.2(b)(1) requires the Secretary of Administration and the Chief of Health Care Reform to submit a report on current and additional strategies to achieve a more comprehensive health

More information

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine

More information

2011 Opioid Treatment Program (OTP) Survey

2011 Opioid Treatment Program (OTP) Survey 20 Opioid Treatment Program (OTP) Survey Data on Substance Abuse Treatment Facilities with OTPs DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Acknowledgments

More information

Effective Treatment Strategies for Adolescent Heroin and Opiate Use. Chris Gleason, MA, CAADC, MAATP Director Rosecrance McHenry County

Effective Treatment Strategies for Adolescent Heroin and Opiate Use. Chris Gleason, MA, CAADC, MAATP Director Rosecrance McHenry County Effective Treatment Strategies for Adolescent Heroin and Opiate Use Chris Gleason, MA, CAADC, MAATP Director Rosecrance McHenry County Learning Objectives The unique challenges related to clinical work

More information

Medicaid Behavioral Health Clinic Rehabilitation Services Manual

Medicaid Behavioral Health Clinic Rehabilitation Services Manual Medicaid Behavioral Health Clinic Rehabilitation Services Manual WV DHHR BUREAU FOR MEDICAL SERVICES JUNE 16, 2014 Charleston, WV Clinic/Rehab Collaboration Over the past year, BMS, BHHF, behavioral health

More information

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to 2012 Page 1 of 6 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:

More information

Medical and Rehabilitation Innovations Buprenorphine and Chronic Pain

Medical and Rehabilitation Innovations Buprenorphine and Chronic Pain Medical and Rehabilitation Innovations Buprenorphine and Chronic Pain BACKGROUND Buprenorphine is a powerful semi-synthetic opioid medication used primarily to treat opioid dependence or narcotic addiction

More information

BUPRENORPHINE TREATMENT. Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist s Courses

BUPRENORPHINE TREATMENT. Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist s Courses BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist s Courses A Generalist s course Developed by the Mountain West ATTC - 1 - Introduction The main goal

More information

Beyond SBIRT: Integrating Addiction Medicine into Primary Care

Beyond SBIRT: Integrating Addiction Medicine into Primary Care Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison

More information

Testimony. For Members of the. House Health & Aging Subcommittee on Opiate Addiction Treatment and Reform. Janet Shaw, MBA, Executive Director

Testimony. For Members of the. House Health & Aging Subcommittee on Opiate Addiction Treatment and Reform. Janet Shaw, MBA, Executive Director Testimony For Members of the House Health & Aging Subcommittee on Opiate Addiction Treatment and Reform Janet Shaw, MBA, Executive Director On behalf of the Ohio Psychiatric Physicians Association Interested

More information

Medication Assisted Treatment for Opioid Use Disorders. AGENCY: Substance Abuse and Mental Health Services Administration (SAMHSA),

Medication Assisted Treatment for Opioid Use Disorders. AGENCY: Substance Abuse and Mental Health Services Administration (SAMHSA), This document is scheduled to be published in the Federal Register on 07/08/2016 and available online at http://federalregister.gov/a/2016-16120, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

Prescription Monitoring Program. One Agency s s Experience. Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA

Prescription Monitoring Program. One Agency s s Experience. Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA Prescription Monitoring Program One Agency s s Experience Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA Agency Description Private non-profit, founded 1973 $8.5 M annual budget; staff

More information

The Opioid Epidemic. Division of Care and Treatment Services (DCTS) Bureau of Prevention,Treatment and Recovery. Wisconsin

The Opioid Epidemic. Division of Care and Treatment Services (DCTS) Bureau of Prevention,Treatment and Recovery. Wisconsin The Opioid Epidemic Division of Care and Treatment Services (DCTS) Bureau of Prevention,Treatment and Recovery Wisconsin 1 Actions to Prevent Opioid Harm and Abuse Education Prescriber education Community

More information

Behavioral Health Barometer. Virginia, 2014

Behavioral Health Barometer. Virginia, 2014 Behavioral Health Barometer Virginia, 2014 Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International under contract No. 283

More information

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to 2012 Page 1 of 8 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:

More information

National Survey of Substance Abuse Treatment Services (N-SSATS): 2013 Data on Substance Abuse Treatment Facilities

National Survey of Substance Abuse Treatment Services (N-SSATS): 2013 Data on Substance Abuse Treatment Facilities National Survey of Substance Abuse Treatment Services (N-SSATS): 2013 Data on Substance Abuse Treatment Facilities DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration

More information

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration

More information

TESTIMONY. March 17, 2014. Rutland, VT

TESTIMONY. March 17, 2014. Rutland, VT Community Solutions to Breaking the Cycle of Heroin & Opioid Addiction TESTIMONY Harry Chen, MD, Commissioner of Health March 17, 2014 Senate Committee on the Judiciary Franklin Conference Center at the

More information

Behavioral Health Barometer. Oklahoma, 2014

Behavioral Health Barometer. Oklahoma, 2014 Behavioral Health Barometer Oklahoma, 2014 Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International under contract No. 283

More information

Acronyms for the Prevention and Treatment of Substance Use Disorders. Prepared by Mental Health Legal Advisors Committee November 2015

Acronyms for the Prevention and Treatment of Substance Use Disorders. Prepared by Mental Health Legal Advisors Committee November 2015 s for the Prevention and Treatment of Substance Use Disorders Prepared by Mental Health Legal Advisors Committee November 2015 Acro ABH ACA A- CRA ACC Association A statewide association ABH of Behavioral

More information

Behavioral Health Barometer. Mississippi, 2014

Behavioral Health Barometer. Mississippi, 2014 Behavioral Health Barometer Mississippi, 2014 Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International under contract No.

More information

John R. Kasich, Governor Orman Hall, Director

John R. Kasich, Governor Orman Hall, Director John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic

More information

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,

More information

Medication is not a part of treatment.

Medication is not a part of treatment. Medication is not a part of treatment. Medication can be an effective part of treatment. Medication is used in the treatment of many diseases, including addiction. Medical decisions must be made by trained

More information

CLINICAL TRIALS NETWORK

CLINICAL TRIALS NETWORK THE UNIVERSITY OF GEORGIA CLINICAL TRIALS NETWORK COUNSELOR-LEVEL DATA ON EVIDENCE-BASED TREATMENT PRACTICES National Treatment Center Study Summary Report No. 11 February 2006 INSTITUTE FOR BEHAVIORAL

More information

Drug Medi-Cal. What this is about...

Drug Medi-Cal. What this is about... Drug Medi-Cal Organized Delivery System Waiver Challenges and Opportunities What this is about... Expanding availability of SUD treatment for low income residents of California. Creating a continuum of

More information

Medication-Assisted Treatment for Opioid Addiction

Medication-Assisted Treatment for Opioid Addiction Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid

More information

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California 2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California FRIDAY, FEBRUARY 6, 2015: 9:30am - 10:30am Opioid Addiction and Buprenorphine Use * Presented by

More information

Testimony of The New York City Department of Health and Mental Hygiene. before the

Testimony of The New York City Department of Health and Mental Hygiene. before the Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid

More information

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment

More information

Office-Based Treatment of Opioid Dependence

Office-Based Treatment of Opioid Dependence Office-Based Treatment of Opioid Dependence Saturday, November 5, 2011 12:30 PM to 5:30 PM Mason General Hospital, Shelton, Washington PROGRAM OVERVIEW Washington State is currently facing an epidemic

More information

Ambulatory Patient Groups (APG) Policy and Medicaid Billing Guidance OASAS Certified Outpatient Chemical Dependence Programs

Ambulatory Patient Groups (APG) Policy and Medicaid Billing Guidance OASAS Certified Outpatient Chemical Dependence Programs Ambulatory Patient Groups (APG) Policy and Medicaid Billing Guidance OASAS Certified Outpatient Chemical Dependence Programs www.oasas.ny.gov TABLE OF CONTENTS SECTION: PAGE 1. Background and Introduction

More information

DIVISION OF MENTAL HEALTH AND ADDICTION SERVICES ADMINISTRATIVE BULLETIN 3:38

DIVISION OF MENTAL HEALTH AND ADDICTION SERVICES ADMINISTRATIVE BULLETIN 3:38 DIVISION OF MENTAL HEALTH AND ADDICTION SERVICES ADMINISTRATIVE BULLETIN 3:38 Effective Date: May 21, 2014 SUBJECT: Guidelines for Use of the Prescription Drug Monitoring in Opioid Treatment Programs I.

More information

Training rural practitioners to use buprenorphine: Using The Change Book to facilitate technology transfer

Training rural practitioners to use buprenorphine: Using The Change Book to facilitate technology transfer Journal of Substance Abuse Treatment 26 (2004) 203 208 Regular article Training rural practitioners to use buprenorphine: Using The Change Book to facilitate technology transfer Dennis McCarty a, *, Traci

More information

Care Management Council submission date: August 2013. Contact Information

Care Management Council submission date: August 2013. Contact Information Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing

More information

Opioid Use Disorder Treatment and Overdose Interventions

Opioid Use Disorder Treatment and Overdose Interventions Opioid Use Disorder Treatment and Overdose Interventions Caleb Banta-Green PhD, MPH, MSW Senior Research Scientist Alcohol & Drug Abuse Institute Affiliate Associate Professor School of Public Health Affiliate

More information

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal

More information

A Nurse Practitioner led opiate substitution prescribing clinic The

A Nurse Practitioner led opiate substitution prescribing clinic The A Nurse Practitioner led opiate substitution prescribing clinic The X First Forty Fifty Four Stephen Ling Nurse Practitioner Drug and Alcohol, Hunter New England Local Health District Conjoint Teacher,

More information

Opioid overdose can occur when a patient misunderstands the directions

Opioid overdose can occur when a patient misunderstands the directions Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription

More information

Medication-Assisted Treatment Introduction and Primary Care Update. UNECOM Alumni CME Program 2014 Joseph Py, D.O.

Medication-Assisted Treatment Introduction and Primary Care Update. UNECOM Alumni CME Program 2014 Joseph Py, D.O. Medication-Assisted Treatment Introduction and Primary Care Update UNECOM Alumni CME Program 2014 Joseph Py, D.O. Medication-Assisted Treatment (MAT) - any treatment for opioid addiction that includes

More information

ANCILLARY STABILIZATION AND WITHDRAWAL. The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting

ANCILLARY STABILIZATION AND WITHDRAWAL. The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting ANCILLARY STABILIZATION AND WITHDRAWAL The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting About CASAColumbia A science-based, multidisciplinary organization Focused on transforming

More information

NIAA Research Findings

NIAA Research Findings NIAA Research Findings Summary: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Research Findings Orientation to Naltrexone and the Integration of Medication into State Treatment Systems. Posted

More information

Governor s Task Force on Mental Health and Substance Use. www.ncdhhs.gov/mhsu

Governor s Task Force on Mental Health and Substance Use. www.ncdhhs.gov/mhsu Governor s Task Force on Mental Health and Substance Use www.ncdhhs.gov/mhsu Problem Statement 97 Painkiller prescriptions per 100 North Carolinians Number of deaths by drug overdose in North Carolina

More information

Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008

Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008 Treatment Episode Data Set The TEDS Report July 15, 010 Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 008 In Brief The proportion of all substance abuse treatment admissions

More information

BUPRENORPHINE TREATMENT

BUPRENORPHINE TREATMENT BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West

More information

Southlake Psychiatry. Suboxone Contract

Southlake Psychiatry. Suboxone Contract Suboxone Contract Thank you for considering Southlake Psychiatry for your Suboxone treatment. Opiate Addiction is a serious condition for which you may find relief with Suboxone treatment. In order to

More information

1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve?

1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve? RI Mental Health Summit Lightning Round Q&A s June 8, 2015 Opiate Addiction Epidemic 1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve? 2) What would

More information

Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS)

Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS) Initial REMS approval: 02/2013 Most recent modification: 06/2015 Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS) This REMS applies

More information

NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES. PART He-W 513 SUBSTANCE USE DISORDER (SUD) TREATMENT AND RECOVERY SUPPORT SERVICES

NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES. PART He-W 513 SUBSTANCE USE DISORDER (SUD) TREATMENT AND RECOVERY SUPPORT SERVICES CHAPTER He-W 500 MEDICAL ASSISTANCE PART He-W 513 SUBSTANCE USE DISORDER (SUD) TREATMENT AND RECOVERY SUPPORT SERVICES He-W 513.01 Purpose. The purpose of this part is to establish the procedures and requirements

More information

Behavioral Health Barometer. United States, 2014

Behavioral Health Barometer. United States, 2014 Behavioral Health Barometer United States, 2014 Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International under contract No.

More information

2008 Magellan Health Services, Inc. This document is the proprietary information of Magellan Health Services, Inc. and its affiliates.

2008 Magellan Health Services, Inc. This document is the proprietary information of Magellan Health Services, Inc. and its affiliates. Resources for Office Based Opioid Treatment Providers Table of Contents Introduction About OBOT Resources to Support OBOT Best Practices Overcoming Logistical Issues Complying with DEA Requirements Reducing

More information